查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1662654

2030 年癌症治療市場新型藥物傳遞系統預測：按藥物類型、輸送方式、藥物釋放類型、技術、應用、最終用戶和地區進行全球分析

Novel Drug Delivery Systems in Cancer Therapy Market Forecasts to 2030 - Global Analysis By Drug Type, Delivery Method, Drug Release Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，腫瘤學新型藥物輸送系統的全球市場規模預計在 2024 年將達到 183.8 億美元，到 2030 年將達到 316.9 億美元，預測期內的複合年成長率為 9.5%。

將抗癌藥物精確、有效分配到特定部位的先進技術稱為癌症治療中的新型藥物傳輸系統。這些系統包括聚合物、脂質體、奈米顆粒等，旨在減少副作用、提高藥物化合物的生物生物有效性並全面提高治療效果。這些技術透過將藥物直接輸送到癌細胞和腫瘤，最大限度地提高治療效果，同時減少對附近健康組織的傷害，為癌症治療帶來了希望。

個人化醫療日益受到關注

對個人化治療的日益重視是推動癌症治療新型藥物輸送系統 (NDDS) 市場發展的主要因素。個人化醫療根據患者的基因組成、分子特徵和腫瘤特徵制定治療方案，可以實現更精確、更有效的癌症治療。 NDDS 對這項策略至關重要，因為它們有助於將藥物分佈到特定的癌細胞，從而減少對良好組織的傷害並改善治療效果。這種精確度可以減少副作用並提高患者對治療計劃的依從性。尖端 NDDS 技術的創造仍然是現代癌症治療計劃的重要組成部分，隨著個人化醫療需求的增加，它支持了市場的擴張。

開發成本高

NDDS 所需的先進技術（如樹狀聚合物、脂質體和奈米粒子）需要獨特​​的材料、複雜的製造程序和大量的經驗。還需要進行大量的臨床前和臨床測試以確保這些系統的安全性和有效性。特別是在資源有限的環境中，這些高昂的費用可能使中小型公司難以進入市場，也可能導致治療成本增加，限制患者獲得治療的機會。簡而言之，NDDS 的開發成本阻礙了其廣泛採用和商業化。

增加研發投入

對更有效、更有針對性和個人化的癌症治療的需求日益成長，推動了對新型藥物輸送系統 (NDDS) 的研究和開發 (R&D) 投資的增加。研發工作重點是開發先進的藥物傳遞技術，如奈米粒子、脂質體和膠束，以提高藥物療效、最大限度地減少副作用並提高患者的依從性。製藥和生技公司也大力投資創新藥物輸送系統，以解決傳統治療方法的局限性，如生物有效性差和全身毒性。不斷增加的研發投入正在加速開發新型、更有效、更安全的癌症治療藥物傳遞方法。

特定輸送系統的臨床證據有限

某些新型藥物輸送系統（NDDS）的臨床資料缺乏仍然是癌症治療市場的一個主要障礙。許多 NDDS 方法，包括某些奈米粒子配方和基於基因的遞送系統，在臨床前研究中已顯示出良好的前景，但尚未在人體臨床試驗中證明持續有效。監管部門核准的延遲可能會阻礙這些技術的廣泛應用。為了使新的 NDDS 技術成功並納入標準癌症治療，需要進行更徹底和大規模的臨床測試以確定這些技術的風險和益處。

COVID-19 的影響

COVID-19 疫情對癌症治療中使用的創新藥物輸送系統 (NDDS) 市場產生了重大影響。臨床測試程序和供應鏈的中斷推遲了新治療方法的開發和核准。此外，由於醫療資源被重新用於應對新冠肺炎，對癌症治療的關注度有所降低。此外，癌症患者在疫情期間更加脆弱，這使得他們的治療計劃更加複雜。這凸顯了需要更有效率、更有針對性的藥物傳遞系統來在這種充滿挑戰的環境下改善患者的治療效果。

預測期內化療藥物領域預計將實現最大幅度成長

由於化療藥物在癌症治療中的廣泛應用，預計在預測期內將佔據最大的市場佔有率。 NDDS 技術可透過提高藥物溶解度、更精準地針對癌細胞和降低全身毒性來增強化療效果。這些系統可以實現控制釋放，最大限度地減少副作用並最大限度地提高治療效果。對改善化療結果同時盡量減少副作用的需求日益增加，這加速了 NDDS 和化療藥物的進一步發展和整合。

預計預測期內醫院部門將以最高的複合年成長率成長。

預計預測期內醫院部門將呈現最高的成長率。作為領先的癌症治療中心，該醫院採用先進的 NDDS 來提高癌症治療的效果、減少副作用並改善患者的治療效果。臨床實踐中對個人化和標靶治療的需求日益成長，鼓勵醫院投資這些創新的藥物傳遞系統，最終促進它們的採用並加速它們融入標準癌症治療方案。

比最大的地區

在預測期內，預計亞太地區將佔據最大的市場佔有率，這得益於癌症發病率的上升、醫療保健基礎設施的改善以及醫療保健支出的增加。世界各國政府都在投資先進的醫療技術，對個人化醫療的認知不斷增強，進一步推動了對 NDDS 的需求。此外，亞太地區龐大的患者群體，加上生物技術和製藥行業的快速發展，使其成為開發和採用創新癌症治療方案的關鍵市場。

複合年成長率最高的地區

預計北美地區在預測期內將呈現最高的複合年成長率。這是因為其擁有強大的醫療基礎設施、先進的研發能力以及高昂的醫療成本。該地區對個人化癌症治療的日益重視，加上對精準醫療的日益重視，正在推動對 NDDS 技術的需求。此外，FDA 等機構的監管支援以及主要製藥和生物技術公司的存在正在加速北美癌症治療創新藥物傳輸系統的開發和採用。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場參與企業（最多 3 家公司）進行全面分析
    • 主要企業的 SWOT 分析（最多 3 家公司）
  • 地理細分
    • 根據客戶興趣對主要國家進行市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭性基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二手研究資料資訊來源
    • 先決條件

第3章 市場走勢分析

  • 介紹
  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

第 5 章。

  • 介紹
  • 化療藥物
  • 免疫療法
  • 標靶治療
  • 荷爾蒙療法
  • 基因治療
  • 其他藥物類型

6. 全球癌症治療市場新型藥物傳輸系統依輸送方式分類

  • 介紹
  • 基於奈米顆粒的藥物輸送
  • 基於微球的藥物輸送
  • 基於脂質體的藥物輸送
  • 聚合物藥物輸送
  • 透過注射和輸注輸送藥物
  • 植入式藥物傳輸系統
  • 其他

第 7 章 癌症治療中新型藥物傳輸系統的全球市場（按藥物釋放類型）

  • 介紹
  • 持續釋放
  • 控釋
  • 目標發布

8. 全球癌症治療市場新型藥物傳輸系統（按技術）

  • 介紹
  • 奈米科技
  • 生物技術
  • 聚合物藥物傳輸系統
  • 脂質體和奈米粒子
  • 基因治療輸送系統
  • 其他

第 9 章 全球癌症治療市場新型藥物傳輸系統的應用

  • 介紹
  • 乳癌
  • 肺癌
  • 大腸直腸癌
  • 攝護腺癌
  • 白血病
  • 其他

第 10 章 全球新型藥物輸送系統癌症治療市場（依最終用戶分類）

  • 介紹
  • 醫院
  • 癌症研究所
  • 專科門診
  • 居家醫療
  • 其他

第 11 章全球癌症治療新型藥物傳輸系統市場（按地區）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司概況

  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • Roche Holding AG
  • Eli Lilly and Company
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Sanofi SA
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Amgen Inc.
  • Celgene Corporation
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Gilead Sciences, Inc.
  • Biocon Limited
  • Mylan NV
Product Code: SMRC28515

According to Stratistics MRC, the Global Novel Drug Delivery Systems in Cancer Therapy Market is accounted for $18.38 billion in 2024 and is expected to reach $31.69 billion by 2030 growing at a CAGR of 9.5% during the forecast period. Advanced technologies created to improve the accurate and efficient distribution of cancer drugs to specific areas are referred to as novel drug delivery systems in cancer therapy. These systems, which include polymers, liposomes, and nanoparticles, are designed to decrease adverse effects, boost the bioavailability of medicinal compounds, and enhance treatment efficacy overall. These technologies provide promising options in cancer therapy by delivering medications directly to cancer cells or tumors, maximizing therapeutic efficacy while reducing harm to nearby healthy tissues.

Market Dynamics:

Driver:

Increased focus on personalized medicine

Growing emphasis on individualized care is a major factor propelling the market for novel drug delivery systems (NDDS) in cancer treatment. More accurate and efficient cancer treatments are made possible by personalized medicine, which adjusts treatment plans according to a patient's genetic composition, molecular profile, and tumor features. By making it easier to distribute medications to particular cancer cells, NDDS are essential to this strategy because they reduce harm to good tissue and improve therapy results. This accuracy lowers adverse effects and increases patient compliance with treatment plans. The creation of cutting-edge NDDS technology remains a vital part of contemporary cancer treatment plans, supporting market expansion as the need for tailored medicines increases.

Restraint:

High development costs

The sophisticated technologies needed for NDDS, like dendrimers, liposomes, and nanoparticles, require unique materials, intricate manufacturing procedures, and a great deal of experience. To guarantee the security and effectiveness of these systems, a great deal of preclinical and clinical testing is also required. Particularly in environments with limited resources, these exorbitant expenses may make it more difficult for smaller businesses to enter the market and may also lead to higher treatment costs, which would limit patient access. This means that the cost of developing NDDS prevents them from being widely adopted and commercialized.

Opportunity:

Growing research and development investments

The growing need for more effective, targeted, and personalized cancer treatments is driving an increase in research and development (R&D) investments in Novel Drug Delivery Systems (NDDS). R&D efforts are focused on developing advanced drug delivery technologies, such as nanoparticles, liposomes, and micelles, which enhance drug efficacy, minimize side effects, and improve patient compliance. Pharmaceutical and biotechnology companies are also investing heavily in innovative drug delivery systems to address the limitations of conventional therapies, such as poor bioavailability and systemic toxicity. Increased R&D investments accelerate the development of novel, more efficient, and safe drug delivery options for cancer treatment.

Threat:

Limited clinical evidence for certain delivery systems

Insufficient clinical data for specific Novel Drug Delivery Systems (NDDS) continues to be a major obstacle in the market for cancer treatments. Many NDDS methods, including specific nanoparticle formulations and gene-based delivery systems, have shown promise in preclinical research but have not yet proven to be consistently effective in human clinical trials. The widespread deployment of these technologies may be hampered by the potential delay in regulatory approval. For emerging NDDS technologies to succeed and be incorporated into standard cancer treatment, more thorough, extensive clinical trials are required to confirm the hazards and advantages of these technologies.

Covid-19 Impact

The COVID-19 pandemic has had a significant impact on the market for innovative drug delivery systems (NDDS) used in cancer treatment. The development and approval of new therapies have been delayed by disruptions in clinical trial procedures and supply chains. Cancer therapies also received less attention as a result of healthcare resources being redirected to COVID-19 management. Additionally, because cancer patients were more vulnerable during the pandemic, their treatment plans were more complex. This highlights the need for more efficient and focused medication delivery systems to improve patient outcomes in this difficult setting.

The chemotherapy drugs segment is expected to be the largest during the forecast period

The chemotherapy drugs segment is expected to account for the largest market share during the forecast period, due to their widespread use in cancer treatment. NDDS technologies enhance the effectiveness of chemotherapy by improving drug solubility, targeting cancer cells more precisely, and reducing systemic toxicity. These systems allow for controlled release, minimizing side effects and maximizing therapeutic impact. The growing need to improve chemotherapy outcomes while minimizing adverse effects fuels further development and integration of NDDS with chemotherapy agents.

The hospitals segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospitals segment is predicted to witness the highest growth rate, as primary centers for cancer treatment, hospitals are adopting advanced NDDS to enhance the efficacy of cancer therapies, reduce side effects, and improve patient outcomes. The increasing demand for personalized and targeted therapies in clinical settings pushes hospitals to invest in these innovative drug delivery systems, ultimately promoting their adoption and accelerating their integration into standard cancer treatment protocols.

Region with largest share:

During the forecast period, Asia Pacific region is expected to hold the largest market share, driven by rising cancer incidence, improving healthcare infrastructure, and increasing healthcare expenditure. Governments are investing in advanced medical technologies, while growing awareness of personalized medicine further boosts demand for NDDS. Additionally, the region's large patient population, combined with rapid advancements in biotechnology and pharmaceutical industries, positions Asia-Pacific as a key market for the development and adoption of innovative cancer treatment solutions.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust healthcare infrastructure, advanced research and development capabilities, and high healthcare spending. The region's focus on precision medicine, along with a growing emphasis on personalized cancer treatments, fuels demand for NDDS technologies. Additionally, regulatory support from agencies like the FDA, along with the presence of leading pharmaceutical and biotech companies accelerates the development and adoption of innovative drug delivery systems for cancer therapy in North America.

Key players in the market

Some of the key players profiled in the Novel Drug Delivery Systems in Cancer Therapy Market include Johnson & Johnson, Pfizer Inc., Novartis AG, Merck & Co., Inc., Roche Holding AG, Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Amgen Inc., Celgene Corporation, Bayer AG, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Biocon Limited, and Mylan N.V.

Key Developments:

In June 2024, Bristol-Myers Squibb Company received FDA accelerated approval for KRAZATI (adagrasib) in combination with cetuximab, a targeted treatment for KRASG12C-mutated CRC patients who had undergone prior chemotherapy, based on ORR and DOR results.

In January 2024, Johnson & Johnson acquired Ambrx Biopharma, a clinical-stage biopharmaceutical company, in a cash merger deal valued at approximately USD 2.0 billion, with estimated cash on hand deducted.

Drug Types Covered:

  • Chemotherapy Drugs
  • Immunotherapy Drugs
  • Targeted Therapy Drugs
  • Hormonal Therapy Drugs
  • Gene Therapy Drugs
  • Other Drug Types

Delivery Methods Covered:

  • Nanoparticle-Based Drug Delivery
  • Microsphere-Based Drug Delivery
  • Liposome-Based Drug Delivery
  • Polymeric Drug Delivery
  • Injection & Infusion Drug Delivery
  • Implantable Drug Delivery Systems
  • Other Delivery Methods

Drug Release Types Covered:

  • Sustained Release
  • Controlled Release
  • Targeted Release

Technologies Covered:

  • Nanotechnology
  • Biotechnology
  • Polymeric Drug Delivery Systems
  • Liposomes and Nanoparticles
  • Gene Therapy Delivery Systems
  • Other Technologies

Applications Covered:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Leukemia
  • Other Applications

End Users Covered:

  • Hospitals
  • Cancer Research Institutes
  • Specialty Clinics
  • Home Care Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Chemotherapy Drugs
  • 5.3 Immunotherapy Drugs
  • 5.4 Targeted Therapy Drugs
  • 5.5 Hormonal Therapy Drugs
  • 5.6 Gene Therapy Drugs
  • 5.7 Other Drug Types

6 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Delivery Method

  • 6.1 Introduction
  • 6.2 Nanoparticle-Based Drug Delivery
  • 6.3 Microsphere-Based Drug Delivery
  • 6.4 Liposome-Based Drug Delivery
  • 6.5 Polymeric Drug Delivery
  • 6.6 Injection & Infusion Drug Delivery
  • 6.7 Implantable Drug Delivery Systems
  • 6.8 Other Delivery Methods

7 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Drug Release Type

  • 7.1 Introduction
  • 7.2 Sustained Release
  • 7.3 Controlled Release
  • 7.4 Targeted Release

8 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Technology

  • 8.1 Introduction
  • 8.2 Nanotechnology
  • 8.3 Biotechnology
  • 8.4 Polymeric Drug Delivery Systems
  • 8.5 Liposomes and Nanoparticles
  • 8.6 Gene Therapy Delivery Systems
  • 8.7 Other Technologies

9 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Application

  • 9.1 Introduction
  • 9.2 Breast Cancer
  • 9.3 Lung Cancer
  • 9.4 Colorectal Cancer
  • 9.5 Prostate Cancer
  • 9.6 Leukemia
  • 9.7 Other Applications

10 Global Novel Drug Delivery Systems in Cancer Therapy Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Cancer Research Institutes
  • 10.4 Specialty Clinics
  • 10.5 Home Care Settings
  • 10.6 Other End Users

11 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Johnson & Johnson
  • 13.2 Pfizer Inc.
  • 13.3 Novartis AG
  • 13.4 Merck & Co., Inc.
  • 13.5 Roche Holding AG
  • 13.6 Eli Lilly and Company
  • 13.7 AbbVie Inc.
  • 13.8 Bristol-Myers Squibb Company
  • 13.9 Sanofi S.A.
  • 13.10 AstraZeneca PLC
  • 13.11 GlaxoSmithKline PLC
  • 13.12 Amgen Inc.
  • 13.13 Celgene Corporation
  • 13.14 Bayer AG
  • 13.15 Teva Pharmaceutical Industries Ltd.
  • 13.16 Gilead Sciences, Inc.
  • 13.17 Biocon Limited
  • 13.18 Mylan N.V.

List of Tables

  • Table 1 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Drug Type (2022-2030) ($MN)
  • Table 3 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Chemotherapy Drugs (2022-2030) ($MN)
  • Table 4 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Immunotherapy Drugs (2022-2030) ($MN)
  • Table 5 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Targeted Therapy Drugs (2022-2030) ($MN)
  • Table 6 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Hormonal Therapy Drugs (2022-2030) ($MN)
  • Table 7 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Gene Therapy Drugs (2022-2030) ($MN)
  • Table 8 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Other Drug Types (2022-2030) ($MN)
  • Table 9 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Delivery Method (2022-2030) ($MN)
  • Table 10 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Nanoparticle-Based Drug Delivery (2022-2030) ($MN)
  • Table 11 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Microsphere-Based Drug Delivery (2022-2030) ($MN)
  • Table 12 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Liposome-Based Drug Delivery (2022-2030) ($MN)
  • Table 13 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Polymeric Drug Delivery (2022-2030) ($MN)
  • Table 14 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Injection & Infusion Drug Delivery (2022-2030) ($MN)
  • Table 15 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Implantable Drug Delivery Systems (2022-2030) ($MN)
  • Table 16 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Other Delivery Methods (2022-2030) ($MN)
  • Table 17 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Drug Release Type (2022-2030) ($MN)
  • Table 18 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Sustained Release (2022-2030) ($MN)
  • Table 19 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Controlled Release (2022-2030) ($MN)
  • Table 20 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Targeted Release (2022-2030) ($MN)
  • Table 21 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Technology (2022-2030) ($MN)
  • Table 22 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Nanotechnology (2022-2030) ($MN)
  • Table 23 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Biotechnology (2022-2030) ($MN)
  • Table 24 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Polymeric Drug Delivery Systems (2022-2030) ($MN)
  • Table 25 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Liposomes and Nanoparticles (2022-2030) ($MN)
  • Table 26 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Gene Therapy Delivery Systems (2022-2030) ($MN)
  • Table 27 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 28 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Application (2022-2030) ($MN)
  • Table 29 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Breast Cancer (2022-2030) ($MN)
  • Table 30 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Lung Cancer (2022-2030) ($MN)
  • Table 31 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Colorectal Cancer (2022-2030) ($MN)
  • Table 32 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Prostate Cancer (2022-2030) ($MN)
  • Table 33 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Leukemia (2022-2030) ($MN)
  • Table 34 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 35 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By End User (2022-2030) ($MN)
  • Table 36 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 37 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Cancer Research Institutes (2022-2030) ($MN)
  • Table 38 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 39 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Home Care Settings (2022-2030) ($MN)
  • Table 40 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.